---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-22-000041"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:33:14.860087+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q3 net loss $23.4M; sotagliflozin NDA on track for May 2023; cash $136.2M

## Summary
- Net loss of $23.4M ($0.13 per share) vs $23.1M ($0.16) in Q3 2021.
- Cash and investments $136.2M at Sep 30, 2022, up from $86.7M at Dec 31, 2021 after $94.3M net proceeds from public offering and private placement.
- NDA for sotagliflozin in heart failure accepted, PDUFA target action date May 2023; mid-cycle review meeting completed.
- Final data from RELIEF-DPN-1 (LX9211) in painful diabetic neuropathy to be presented; enrollment complete in RELIEF-PHN-1 study with top-line data expected by year-end.

## SEC filing metadata
- accession: 0001062822-22-000041
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/0001062822-22-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/lxrx-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-22-000041
- JSON: https://secwatch.observer/filing/0001062822-22-000041.json
- Plain text: https://secwatch.observer/filing/0001062822-22-000041.txt

## Key facts
- Earnings Releases
  LEXICON PHARMACEUTICALS, INC. reported the three months ended September 30, 2022 results: net income $23.4 million, or $0.13 per share.
  - Period: the three months ended September 30, 2022
  - Net income: $23.4 million, or $0.13 per share
  - Result: reported results
  source text: Net loss for the third quarter of 2022 was $23.4 million, or $0.13 per share, as compared to a net loss of $23.1 million, or $0.16 per share, in the corresponding period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282222000041/0001062822-22-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.